IP Verse

Crystalline Forms Of N-(4-(4-(Cyclopropylmethyl) Piperazine-1-Carbonyl)Phenyl)Quinoline-8-Sulfonamide

Patent No. EP3713919 (titled "Crystalline Forms Of N-(4-(4-(Cyclopropylmethyl) Piperazine-1-Carbonyl)Phenyl)Quinoline-8-Sulfonamide") was filed by Agios Pharmaceuticals on Nov 21, 2018. The application was issued on Aug 2, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BOTTI & FERRARIMay 2, 2024BOTTI & FERRARI
SANDOZMay 2, 2024TER MEER STEINMEISTER & PARTNER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3713919

AGIOS PHARMACEUTICALS
Application Number
EP18821779A
Filing Date
Nov 21, 2018
Status
Granted And Under Opposition
Jun 30, 2023
Publication Date
Aug 2, 2023
External Links
Slate, Register , Google Patents